Dec 11 (Reuters) - Sanofi SA :

* TWO COMBINATION VACCINE CANDIDATES FOR PREVENTION OF INFLUENZA AND COVID-19 GRANTED FAST TRACK DESIGNATION IN THE US

* FDA GRANTS FAST TRACK DESIGNATION TO SANOFI COMBINATION VACCINE CANDIDATES

* SECOND CANDIDATE COMBINES FLUBLOK AND NOVAVAX COVID-19 VACCINE

* INITIATES PHASE 1/2 STUDIES FOR COMBINATION VACCINE CANDIDATES

* FIRST CANDIDATE COMBINES FLUZONE HIGH-DOSE AND NOVAVAX COVID-19 VACCINE

* NOVAVAX COVID-19 VACCINE SHOWS BETTER TOLERABILITY THAN MRNA VACCINES

Source text: Further company coverage:

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))